It was found that Eliquis (Apixaban)'s cumulative prescription amount for generics, which faced a crisis of compensation for damages due to the Supreme Court decision made earlier this month, reached ₩12.7 billion. With the sale of generics stopped at once after the Supreme Court ruling, generic companies have to pay a significant portion of ₩12.7 billion. Eliquis' Rx performance is expected to rebound from next month. However, the NOAC (new oral anticoagulant) market is stagnating, and it is unclear how long it will recover.

◆Eliquis' generics withdrew from the market after recording ₩12.7 billion

Eliquis' generics withdrew from the market after recording ₩